請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20326
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(Yen-Ping Kuo),陳信銘(Hsin-Ming Chen) | |
dc.contributor.author | ERH-HSIANG WANG | en |
dc.contributor.author | 王爾祥 | zh_TW |
dc.date.accessioned | 2021-06-08T02:45:15Z | - |
dc.date.copyright | 2018-02-22 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-12-12 | |
dc.identifier.citation | Reference
1 Sirsat, S. M. & Khanolkar, V. R. Submucous fibrosis of the palate and pillars of the fauces. Indian J Med Sci 16, 189-197 (1962). 2 Pindborg, J. J. et al. Oral submucous fibrosis as a precancerous condition. Scand J Dent Res 92, 224-229 (1984). 3 Pillai, R., Balaram, P. & Reddiar, K. S. Pathogenesis of oral submucous fibrosis. Relationship to risk factors associated with oral cancer. Cancer 69, 2011-2020 (1992). 4 Anura, A. et al. Computer-aided molecular pathology interpretation in exploring prospective markers for oral submucous fibrosis progression. Head Neck 38, 653-669, doi:10.1002/hed.23962 (2016). 5 Xie, X. et al. MALDI imaging reveals NCOA7 as a potential biomarker in oral squamous cell carcinoma arising from oral submucous fibrosis. Oncotarget 7, 59987-60004, doi:10.18632/oncotarget.11046 (2016). 6 Yoithapprabhunath, T. R. et al. Pathogenesis and therapeutic intervention of oral submucous fibrosis. J Pharm Bioallied Sci 5, S85-88, doi:10.4103/0975-7406.113303 (2013). 7 Wang, Y. Y. et al. Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 14, 99, doi:10.1186/1472-6831-14-99 (2014). 8 Lian Ie, B., Tseng, Y. T., Su, C. C. & Tsai, K. Y. Progression of precancerous lesions to oral cancer: results based on the Taiwan National Health Insurance Database. Oral Oncol 49, 427-430, doi:10.1016/j.oraloncology.2012.12.004 (2013). 9 Warnakulasuriya, S., Johnson, N. W. & van der Waal, I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36, 575-580, doi:10.1111/j.1600-0714.2007.00582.x (2007). 10 van Wyk, C. W., Grobler-Rabie, A. F., Martell, R. W. & Hammond, M. G. HLA-antigens in oral submucous fibrosis. J Oral Pathol Med 23, 23-27 (1994). 11 Maresky, L. S., de Waal, J., Pretorius, S., van Zyl, A. W. & Wolfaardt, P. Epidemiology of oral precancer and cancer. J Dent Assoc S Afr Suppl 1, 18-20 (1989). 12 Lai, D. R., Chen, H. R., Lin, L. M., Huang, Y. L. & Tsai, C. C. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J Oral Pathol Med 24, 402-406 (1995). 13 Auluck, A., Rosin, M. P., Zhang, L. & Sumanth, K. N. Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature. J Can Dent Assoc 74, 735-740 (2008). 14 Dave, B. J., Trivedi, A. H. & Adhvaryu, S. G. Role of areca nut consumption in the cause of oral cancers. A cytogenetic assessment. Cancer 70, 1017-1023 (1992). 15 Haider, S. M., Merchant, A. T., Fikree, F. F. & Rahbar, M. H. Clinical and functional staging of oral submucous fibrosis. Br J Oral Maxillofac Surg 38, 12-15, doi:10.1054/bjom.1999.0062 (2000). 16 Arakeri, G. et al. Breath Alkane as an index of severity for oral submucous fibrosis: A new perspective? Medical Hypotheses 98, 18-20, doi:https://doi.org/10.1016/j.mehy.2016.11.005 (2017). 17 Arakeri, G., Patil, S. G., Ramesh, D. N., Hunasgi, S. & Brennan, P. A. Evaluation of the possible role of copper ions in drinking water in the pathogenesis of oral submucous fibrosis: a pilot study. Br J Oral Maxillofac Surg 52, 24-28, doi:10.1016/j.bjoms.2013.01.010 (2014). 18 Tilakaratne, W. M., Klinikowski, M. F., Saku, T., Peters, T. J. & Warnakulasuriya, S. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42, 561-568, doi:10.1016/j.oraloncology.2005.08.005 (2006). 19 Murti, P. R. et al. Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J Oral Pathol Med 24, 145-152 (1995). 20 Khanna, J. N. & Andrade, N. N. Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. Int J Oral Maxillofac Surg 24, 433-439 (1995). 21 Pindborg, J. J. Oral Precancerous Conditions in South East Asia. Int Dent J 15, 190-199 (1965). 22 Sinor, P. N. et al. A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 19, 94-98 (1990). 23 Pindborg, J. J., Mehta, F. S., Gupta, P. C. & Daftary, D. K. Prevalence of oral submucous fibrosis among 50,915 Indian villagers. Br J Cancer 22, 646-654 (1968). 24 Cox, S. C. & Walker, D. M. Oral submucous fibrosis. A review. Aust Dent J 41, 294-299 (1996). 25 Cerero-Lapiedra, R. et al. Ability of Dental Students in Spain to Identify Potentially Malignant Disorders and Oral Cancer. J Dent Educ 79, 959-964 (2015). 26 Chang, M. C. et al. Areca nut extract and arecoline induced the cell cycle arrest but not apoptosis of cultured oral KB epithelial cells: association of glutathione, reactive oxygen species and mitochondrial membrane potential. Carcinogenesis 22, 1527-1535 (2001). 27 Jeng, J. H., Chang, M. C. & Hahn, L. J. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 37, 477-492 (2001). 28 Sharan, R. N., Schneeweiss, F. H. & Feinendegen, L. E. Neutrons affect ADP-ribosylation of proteins in human kidney T1-cells in vitro. Indian J Biochem Biophys 33, 281-284 (1996). 29 Canniff, J. P., Harvey, W. & Harris, M. Oral submucous fibrosis: its pathogenesis and management. Br Dent J 160, 429-434 (1986). 30 Sharma, D. C. Betel quid and areca nut are carcinogenic without tobacco. Lancet Oncol 4, 587 (2003). 31 Ko, Y. C. et al. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24, 450-453 (1995). 32 Lu, C. T. et al. A case-control study of oral cancer in Changhua County, Taiwan. J Oral Pathol Med 25, 245-248 (1996). 33 Gupta, P. C. & Ray, C. S. Epidemiology of betel quid usage. Ann Acad Med Singapore 33, 31-36 (2004). 34 Humans, I. W. G. o. t. E. o. C. R. t. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum 85, 1-334 (2004). 35 Guh, J. Y., Chen, H. C., Tsai, J. F. & Chuang, L. Y. Betel-quid use is associated with heart disease in women. Am J Clin Nutr 85, 1229-1235 (2007). 36 Guh, J. Y., Chuang, L. Y. & Chen, H. C. Betel-quid use is associated with the risk of the metabolic syndrome in adults. Am J Clin Nutr 83, 1313-1320 (2006). 37 Wang, T. N. et al. Betel chewing and arecoline affects eotaxin-1, asthma and lung function. PLoS One 9, e91889, doi:10.1371/journal.pone.0091889 (2014). 38 Warnakulasuriya, S., Trivedy, C. & Peters, T. J. Areca nut use: an independent risk factor for oral cancer. BMJ 324, 799-800 (2002). 39 Pickwell, S. M., Schimelpfening, S. & Palinkas, L. A. 'Betelmania'. Betel quid chewing by Cambodian women in the United States and its potential health effects. West J Med 160, 326-330 (1994). 40 Gupta, P. C. & Warnakulasuriya, S. Global epidemiology of areca nut usage. Addict Biol 7, 77-83, doi:10.1080/13556210020091437 (2002). 41 Ko, Y. C., Chiang, T. A., Chang, S. J. & Hsieh, S. F. Prevalence of betel quid chewing habit in Taiwan and related sociodemographic factors. J Oral Pathol Med 21, 261-264 (1992). 42 Tseng, S.-K. et al. Arecoline inhibits endothelial cell growth and migration and the attachment to mononuclear cells. Journal of Dental Sciences 9, 258-264, doi:https://doi.org/10.1016/j.jds.2012.12.015 (2014). 43 Deb, S. & Chatterjee, A. Influence of buthionine sulfoximine and reduced glutathione on arecoline-induced chromosomal damage and sister chromatid exchange in mouse bone marrow cells in vivo. Mutagenesis 13, 243-248 (1998). 44 Panigrahi, G. B. & Rao, A. R. Chromosome-breaking ability of arecoline, a major betel-nut alkaloid, in mouse bone-marrow cells in vivo. Mutat Res 103, 197-204 (1982). 45 Shirname, L. P., Menon, M. M. & Bhide, S. V. Mutagenicity of betel quid and its ingredients using mammalian test systems. Carcinogenesis 5, 501-503 (1984). 46 Bales, A. et al. Associations between betel nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study. Psychiatry Res 169, 203-211, doi:10.1016/j.psychres.2008.06.006 (2009). 47 Lin, S. H. et al. Arecoline-induced pro-fibrotic proteins in LLC-PK1 cells are dependent on c-Jun N-terminal kinase. Toxicology 344-346, 53-60, doi:10.1016/j.tox.2016.02.004 (2016). 48 Garg, A., Chaturvedi, P. & Gupta, P. C. A review of the systemic adverse effects of areca nut or betel nut. Indian J Med Paediatr Oncol 35, 3-9, doi:10.4103/0971-5851.133702 (2014). 49 Yu, C. C., Tsai, C. H., Hsu, H. I. & Chang, Y. C. Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral submucous fibrosis. PLoS One 8, e55122, doi:10.1371/journal.pone.0055122 (2013). 50 Peng, W. H., Lee, Y. C., Chau, Y. P., Lu, K. S. & Kung, H. N. Short-term exposure of zebrafish embryos to arecoline leads to retarded growth, motor impairment, and somite muscle fiber changes. Zebrafish 12, 58-70, doi:10.1089/zeb.2014.1010 (2015). 51 Jiang, J. M. et al. Arecoline Induces Neurotoxicity to PC12 Cells: Involvement in ER Stress and Disturbance of Endogenous H2S Generation. Neurochem Res 41, 2140-2148, doi:10.1007/s11064-016-1929-6 (2016). 52 Zheng, L. et al. miR-203 inhibits arecoline-induced epithelial-mesenchymal transition by regulating secreted frizzled-related protein 4 and transmembrane-4 L six family member 1 in oral submucous fibrosis. Oncol Rep 33, 2753-2760, doi:10.3892/or.2015.3909 (2015). 53 Chou, W. W. et al. Arecoline-induced phosphorylated p53 and p21(WAF1) protein expression is dependent on ATM/ATR and phosphatidylinositol-3-kinase in clone-9 cells. J Cell Biochem 107, 408-417, doi:10.1002/jcb.22137 (2009). 54 Stich, H. F., Stich, W. & Lam, P. P. Potentiation of genotoxicity by concurrent application of compounds found in betel quid: arecoline, eugenol, quercetin, chlorogenic acid and Mn2+. Mutat Res 90, 355-363 (1981). 55 Dasgupta, R. et al. Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice. Toxicology 227, 94-104, doi:10.1016/j.tox.2006.07.016 (2006). 56 Jeng, J. H. et al. Effects of areca nut, inflorescence piper betle extracts and arecoline on cytotoxicity, total and unscheduled DNA synthesis in cultured gingival keratinocytes. J Oral Pathol Med 28, 64-71 (1999). 57 Jeng, J. H. et al. Arecoline cytotoxicity on human oral mucosal fibroblasts related to cellular thiol and esterase activities. Food Chem Toxicol 37, 751-756 (1999). 58 Harvey, W., Scutt, A., Meghji, S. & Canniff, J. P. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Arch Oral Biol 31, 45-49 (1986). 59 Chang, Y. C., Tai, K. W., Cheng, M. H., Chou, L. S. & Chou, M. Y. Cytotoxic and non-genotoxic effects of arecoline on human buccal fibroblasts in vitro. J Oral Pathol Med 27, 68-71 (1998). 60 Canniff, J. P. & Harvey, W. The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut. Int J Oral Surg 10, 163-167 (1981). 61 Jeng, J. H., Lan, W. H., Hahn, L. J., Hsieh, C. C. & Kuo, M. Y. Inhibition of the migration, attachment, spreading, growth and collagen synthesis of human gingival fibroblasts by arecoline, a major areca alkaloid, in vitro. J Oral Pathol Med 25, 371-375 (1996). 62 Yang, S. F., Hsieh, Y. S., Tsai, C. H., Chou, M. Y. & Chang, Y. C. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis. Oral Oncol 39, 367-372 (2003). 63 Chang, Y. C., Yang, S. F., Tai, K. W., Chou, M. Y. & Hsieh, Y. S. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol 38, 195-200 (2002). 64 Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13, 952-961, doi:10.1038/nm1613 (2007). 65 Tsai, C. H. et al. Regulation of interleukin-6 expression by arecoline in human buccal mucosal fibroblasts is related to intracellular glutathione levels. Oral Dis 10, 360-364, doi:10.1111/j.1601-0825.2004.01041.x (2004). 66 Tsai, C. H., Yang, S. F., Chen, Y. J., Chou, M. Y. & Chang, Y. C. Raised keratinocyte growth factor-1 expression in oral submucous fibrosis in vivo and upregulated by arecoline in human buccal mucosal fibroblasts in vitro. J Oral Pathol Med 34, 100-105, doi:10.1111/j.1600-0714.2004.00288.x (2005). 67 Ni, W. F., Tsai, C. H., Yang, S. F. & Chang, Y. C. Elevated expression of NF-kappaB in oral submucous fibrosis--evidence for NF-kappaB induction by safrole in human buccal mucosal fibroblasts. Oral Oncol 43, 557-562, doi:10.1016/j.oraloncology.2006.06.007 (2007). 68 Chung-Hung, T., Shun-Fa, Y. & Yu-Chao, C. The upregulation of cystatin C in oral submucous fibrosis. Oral Oncol 43, 680-685, doi:10.1016/j.oraloncology.2006.08.009 (2007). 69 Tsai, C. H., Yang, S. F., Lee, S. S. & Chang, Y. C. Augmented heme oxygenase-1 expression in areca quid chewing-associated oral submucous fibrosis. Oral Dis 15, 281-286 (2009). 70 Chang, Y. C. et al. Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 38, 425-430 (2002). 71 Chen, Y. J. & Chang, L. S. Arecoline-induced death of human leukemia K562 cells is associated with surface up-modulation of TNFR2. J Cell Physiol 227, 2240-2251, doi:10.1002/jcp.22963 (2012). 72 Hsu, Y. H. et al. Association of betel nut chewing with chronic kidney disease: a retrospective 7-year study in Taiwan. Nephrology (Carlton) 16, 751-757, doi:10.1111/j.1440-1797.2011.01489.x (2011). 73 Chang, Y. C. et al. Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1. J Cell Mol Med 18, 698-708, doi:10.1111/jcmm.12219 (2014). 74 Kubiczkova, L., Sedlarikova, L., Hajek, R. & Sevcikova, S. TGF-beta - an excellent servant but a bad master. J Transl Med 10, 183, doi:10.1186/1479-5876-10-183 (2012). 75 Leask, A. & Abraham, D. J. TGF-beta signaling and the fibrotic response. FASEB J 18, 816-827, doi:10.1096/fj.03-1273rev (2004). 76 Chen, W. & Wahl, S. M. TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 5, 62-91 (2002). 77 Letterio, J. J. & Roberts, A. B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16, 137-161, doi:10.1146/annurev.immunol.16.1.137 (1998). 78 Li, M. O. & Flavell, R. A. TGF-beta: a master of all T cell trades. Cell 134, 392-404, doi:10.1016/j.cell.2008.07.025 (2008). 79 Travis, M. A. & Sheppard, D. TGF-beta activation and function in immunity. Annu Rev Immunol 32, 51-82, doi:10.1146/annurev-immunol-032713-120257 (2014). 80 Akhurst, R. J. & Padgett, R. W. Matters of context guide future research in TGFbeta superfamily signaling. Sci Signal 8, re10, doi:10.1126/scisignal.aad0416 (2015). 81 Massague, J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 13, 616-630, doi:10.1038/nrm3434 (2012). 82 Loeffler, I. & Wolf, G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant 29 Suppl 1, i37-i45, doi:10.1093/ndt/gft267 (2014). 83 Zeisberg, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21, 1819-1834, doi:10.1681/ASN.2010080793 (2010). 84 Campanholle, G., Ligresti, G., Gharib, S. A. & Duffield, J. S. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 304, C591-603, doi:10.1152/ajpcell.00414.2012 (2013). 85 Border, W. A., Okuda, S., Languino, L. R. & Ruoslahti, E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 37, 689-695 (1990). 86 Haberstroh, U. et al. TGF-beta stimulates rat mesangial cell proliferation in culture: role of PDGF beta-receptor expression. Am J Physiol 264, F199-205 (1993). 87 Wilson, H. M. et al. Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp Nephrol 1, 343-350 (1993). 88 Kagan, H. M. & Li, W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88, 660-672, doi:10.1002/jcb.10413 (2003). 89 Vadasz, Z. et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 43, 499-507, doi:10.1016/j.jhep.2005.02.052 (2005). 90 Kim, Y. M., Kim, E. C. & Kim, Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38, 145-149, doi:10.1007/s11033-010-0088-0 (2011). 91 Barker, H. E., Cox, T. R. & Erler, J. T. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 12, 540-552, doi:10.1038/nrc3319 (2012). 92 Lopez, B. et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 299, H1-9, doi:10.1152/ajpheart.00335.2010 (2010). 93 Asuncion, L. et al. A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain. Matrix Biol 20, 487-491 (2001). 94 Jourdan-Le Saux, C., Tomsche, A., Ujfalusi, A., Jia, L. & Csiszar, K. Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein. Genomics 74, 211-218, doi:10.1006/geno.2001.6545 (2001). 95 Kim, Y., Boyd, C. D. & Csiszar, K. A new gene with sequence and structural similarity to the gene encoding human lysyl oxidase. J Biol Chem 270, 7176-7182 (1995). 96 Saito, H., Papaconstantinou, J., Sato, H. & Goldstein, S. Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence. J Biol Chem 272, 8157-8160 (1997). 97 Nishikawa, R. et al. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Lett 589, 2136-2145, doi:10.1016/j.febslet.2015.06.005 (2015). 98 Fong, S. F. et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer 46, 644-655, doi:10.1002/gcc.20444 (2007). 99 Offenberg, H., Brunner, N., Mansilla, F., Orntoft Torben, F. & Birkenkamp-Demtroder, K. TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles. Mol Oncol 2, 233-240, doi:10.1016/j.molonc.2008.06.003 (2008). 100 Peng, L. et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 30, 1660-1669, doi:10.1093/carcin/bgp178 (2009). 101 Akiri, G. et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res 63, 1657-1666 (2003). 102 Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226, doi:10.1038/nature04695 (2006). 103 Peinado, H. et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 68, 4541-4550, doi:10.1158/0008-5472.CAN-07-6345 (2008). 104 Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16, 1009-1017, doi:10.1038/nm.2208 (2010). 105 Barker, H. E. et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 71, 1561-1572, doi:10.1158/0008-5472.CAN-10-2868 (2011). 106 Kasashima, H. et al. Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer. Cancer Lett 354, 438-446, doi:10.1016/j.canlet.2014.08.014 (2014). 107 Hase, H. et al. LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC. Mol Cancer Res 12, 1807-1817, doi:10.1158/1541-7786.MCR-14-0233 (2014). 108 Galvan, J. A. et al. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer 112, 1944-1950, doi:10.1038/bjc.2015.177 (2015). 109 Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196, 395-406, doi:10.1083/jcb.201102147 (2012). 110 von Burstin, J. et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137, 361-371, 371 e361-365, doi:10.1053/j.gastro.2009.04.004 (2009). 111 Peinado, H. et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 24, 3446-3458, doi:10.1038/sj.emboj.7600781 (2005). 112 Schietke, R. et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem 285, 6658-6669, doi:10.1074/jbc.M109.042424 (2010). 113 Cano, A., Santamaria, P. G. & Moreno-Bueno, G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol 8, 1095-1108, doi:10.2217/fon.12.105 (2012). 114 Yang, J. et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 7, 13710, doi:10.1038/ncomms13710 (2016). 115 Zhao, Y. et al. Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Biosci Rep, doi:10.1042/BSR20171332 (2017). 116 Moon, H. J., Finney, J., Ronnebaum, T. & Mure, M. Human lysyl oxidase-like 2. Bioorg Chem 57, 231-241, doi:10.1016/j.bioorg.2014.07.003 (2014). 117 Fu, Q., Bai, Y., Liu, Y., Zhou, J. & Zheng, Y. The serum level and significance of lysyl oxidase-like 2 in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol, doi:10.1007/s10067-017-3878-0 (2017). 118 Chien, J. W. et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 43, 1430-1438, doi:10.1183/09031936.00141013 (2014). 119 Choi, S. E. et al. Lysyl oxidaselike 2 is expressed in kidney tissue and is associated with the progression of tubulointerstitial fibrosis. Mol Med Rep 16, 2477-2482, doi:10.3892/mmr.2017.6918 (2017). 120 Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J. & Gheorghiade, M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol 63, 2188-2198, doi:10.1016/j.jacc.2014.01.068 (2014). 121 Sharan, R. N., Mehrotra, R., Choudhury, Y. & Asotra, K. Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 7, e42759, doi:10.1371/journal.pone.0042759 (2012). 122 Kang, J. S., Liu, C. & Derynck, R. New regulatory mechanisms of TGF-β receptor function. Trends in Cell Biology 19, 385-394, doi:http://dx.doi.org/10.1016/j.tcb.2009.05.008 (2009). 123 Flanders, K. C. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85, 47-64, doi:10.1111/j.0959-9673.2004.00377.x (2004). 124 Prime, S. S., Pring, M., Davies, M. & Paterson, I. C. TGF-beta signal transduction in oro-facial health and non-malignant disease (part I). Crit Rev Oral Biol Med 15, 324-336 (2004). 125 Ghosh, A. K., Yuan, W., Mori, Y. & Varga, J. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 19, 3546-3555, doi:10.1038/sj.onc.1203693 (2000). 126 Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res 347, 11-20, doi:10.1007/s00441-011-1201-y (2012). 127 Sethi, A., Mao, W., Wordinger, R. J. & Clark, A. F. Transforming growth factor-beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 52, 5240-5250, doi:10.1167/iovs.11-7287 (2011). 128 Cenizo, V. et al. LOXL as a target to increase the elastin content in adult skin: a dill extract induces the LOXL gene expression. Exp Dermatol 15, 574-581, doi:10.1111/j.1600-0625.2006.00442.x (2006). 129 Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18, 1028-1040, doi:10.1038/nm.2807 (2012). 130 Ovet, H. & Oztay, F. The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions. Biol Trace Elem Res 162, 189-199, doi:10.1007/s12011-014-0142-1 (2014). 131 Brewer, G. J., Dick, R., Ullenbruch, M. R., Jin, H. & Phan, S. H. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98, 2160-2167, doi:10.1016/j.jinorgbio.2004.10.006 (2004). 132 Brewer, G. J., Ullenbruch, M. R., Dick, R., Olivarez, L. & Phan, S. H. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141, 210-216, doi:10.1067/mlc.2003.20 (2003). 133 Raghu, G. et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. The Lancet Respiratory Medicine 5, 22-32, doi:https://doi.org/10.1016/S2213-2600(16)30421-0 (2017). 134 Matsuzaki, S. & Darcha, C. Antifibrotic properties of epigallocatechin-3-gallate in endometriosis. Hum Reprod 29, 1677-1687, doi:10.1093/humrep/deu123 (2014). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20326 | - |
dc.description.abstract | 離氨基氧化酶樣蛋白2 (Lysyl Oxidase-like protein 2, LOXL2)是離胺基氧化酶(lysyl oxidase, LOX)家族的一種分泌型酶。主要功能是催化膠原蛋白與彈性纖維的交叉共價鍵結(cross-linking),以維持胞外基質的硬性及穩定性。被報告和肺、肝、腎等的纖維化有關。口腔黏膜下纖維化症 (oral submucous fibrosis, OSF),是一種不可逆的口腔黏膜纖維性病變。流行病學研究指出,嚼檳榔是口腔黏膜下纖維化症的最主要致病因子。本研究利用免疫組織化學染色方法,探討LOXL2於7例OSF及3例正常口腔黏膜(normal oral mucosa, NOM)中的表現。 結果發現在6例OSF 檢體的表皮細胞和纖維母細胞中都有LOXL2的陽性染色, NOM 則幾乎沒有表現。以檳榔鹼 arecoline 刺激人類頰黏膜纖維母細胞(buccal mucosal fibroblast, BMFs),可以誘導BMF產生LOXL2 表現。OSF纖維母細胞與正常BMF相比,LOXL2在OSF纖維母細胞中也具有較高的表現。前處理TGF-β 中和抗體,TβRI/ALK5的專一性抑制劑SB431542,Smad3的專一性抑制劑SIS3可以抑制BMF中 arecoline誘導的LOXL2 表現。 TGF-β可以誘導BMF的LOXL2 表現。 可見得arecoline 是經由TGF-β訊息傳導路徑誘導BMF 的 LOXL2 表現。此外,前處理兒茶素(Epigallocatechin gallate, EGCG)可抑制arecoline 及TGF-β 誘導的LOXL2 表現。結果顯示EGCG對於預防或治療OSF具有極大的潛力。 | zh_TW |
dc.description.abstract | Lysyl oxidase like protein 2 (LOXL2) is an extracellular copper-dependent amine oxidase that catalyses the cross-linking of collagens and elastin. It has recently been reported to serve a key role in hepatic, renal, and pulmonary fibrosis. Areca nut (AN) chewing is the most important etiological factor in the pathogenesis of oral submucous fibrosis (OSF). We examined the expression of LOXL2 protein in 7 cases of OSF and found elevated LOXL2 staining in fibroblasts and epithelial cells in 6 cases. Arecoline, a main alkaloid found in the areca nut, stimulated LOXL2 synthesis in human buccal mucosal fibroblasts (BMFs). TGFβ-neutralizing antibody, ALK5 specific inhibitor SB431542, Smad3 specific inhibitor SIS3 completely inhibited the arecoline-induced synthesis of LOXL2. Furthermore, TGF-β1 induced LOXL2 expression in BMF. Therefore, arecoline induced LOXL2 expression through TGF-β signal pathway in BMF. Moreover, Pretreated with Epigallocatechin-3-gallate (EGCG) dose-dependently inhibited arecoline-induced LOXL2 expression. In conclusion, EGCG has extreme potential for the prevention or treatment of OSF. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:45:15Z (GMT). No. of bitstreams: 1 ntu-106-R04450007-1.pdf: 1472082 bytes, checksum: 8a0e302671374ac9baa2885216678812 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii CONTENTS iv 中文摘要 vi ABSTRACT vii LIST OF FIGURES viii LIST OF TABLES ix Chapter 1 Introduction 1 1.1 Oral submucous fibroblast (OSF) 1 1.1.1 Introduction of oral submucous fibrosis 1 1.1.2 OSF epidemiology 2 1.1.3 Treatment modality of OSF 3 1.2 Oral cancer 4 1.2.1 Introduction of oral cancer 4 1.3 Arecoline 5 1.3.1 Introduction of arecoline 5 1.3.2 Arecoline and fibrosis relationship 6 1.4 Transforming growth factor-β (TGF-β) 7 1.4.1 Introduction of TGF-β 7 1.4.2 TGF-β and fibrosis relationship 8 1.5 Lysyl oxidase like protein 2 (LOXL2) 9 1.5.1 Introduction of lysyl oxidase like protein 2 (LOXL2) 9 1.5.2 LOXL2 and fibrosis relationship 10 Chapter 2 Materials and Methods 11 2.1 Clinical specimens 11 2.2 Immunohistochemistry 11 2.3 Cell culture 12 2.4 Western blot analysis 13 2.4.1 Protein preparation and electrophoresis 13 2.4.2 Separating gel composition 13 2.4.3 Stacking gel composition 14 2.4.4 Protein transfer and blocking 14 2.4.5 Antibody hybridization 14 2.4.6 Primary antibody information 15 2.4.7 Secondary antibody information 15 2.5 siRNA transfection 16 2.5.1 Reagent 16 2.6 Statistical analysis 16 2.7 Information 17 Chapter 3 Results 19 3.1 High expression of LOXL2 in OSF and BMF treated with arecoline 19 3.2 TGF-β promoting LOXL2 expression through different signal transduction pathways 20 3.3 EGCG and curcumin inhibit LOXL2 expression in BMF 21 3.4 TGF-β induce LOXL2 expression and collagen production in BMF 22 Chapter 4 Discussion 23 Chapter 5 Figures 26 Reference 36 | |
dc.language.iso | en | |
dc.title | 檳榔鹼Arecoline經由TGF-β誘導人類頰黏膜纖維母細胞離氨基氧化酶樣蛋白2表現 | zh_TW |
dc.title | Arecoline Induces LOXL2 Expression via TGF-β Pathway in Buccal Fibroblasts | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 江俊斌,黎萬君 | |
dc.subject.keyword | 離氨基氧化?相關蛋白2,檳榔鹼,口腔黏膜下纖維化症,膠原蛋白,上皮變間質型轉換, | zh_TW |
dc.subject.keyword | LOXL2,Arecoline,OSF,Collagen,EMT, | en |
dc.relation.page | 44 | |
dc.identifier.doi | 10.6342/NTU201703625 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-12-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 1.44 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。